Candel Therapeutics (CADL) Cash from Financing Activities (2020 - 2025)

Candel Therapeutics has disclosed Cash from Financing Activities across 6 years of filings, most recently posting $43.9 million for Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at $43.9 million, down 52.24% year-over-year; the trailing twelve-month figure through Dec 2025 was $56.1 million (down 40.5% YoY), and the FY2025 annual result was $56.1 million, down 40.5% from the prior year.
• Cash from Financing Activities came in at $43.9 million for Q4 2025 at Candel Therapeutics, up from -$3.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $91.9 million in Q4 2024 to a low of -$3.4 million in Q3 2025.
• The 5-year median for Cash from Financing Activities is $333000.0 (2021), against an average of $16.1 million.
• Across the five-year window, Cash from Financing Activities sank 436.11% in 2023 and jumped 76061.16% in 2024, its largest moves.
• Candel Therapeutics' Cash from Financing Activities stood at $71.4 million in 2021, then tumbled by 99.95% to $36000.0 in 2022, then tumbled by 436.11% to -$121000.0 in 2023, then surged by 76061.16% to $91.9 million in 2024, then plunged by 52.24% to $43.9 million in 2025.
• The last three Cash from Financing Activities figures came in at $43.9 million (Q4 2025), -$3.4 million (Q3 2025), and $17.4 million (Q2 2025), per Business Quant data.